MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term ...

Lomecel-B™ is now known as laromestrocel, a cellular therapy for Alzheimer's and hypoplastic left heart syndrome, following WHO approval. Longeveron Inc. has announced that its cellular therapy ...

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with ...

New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated ...

Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s disease This encouraging clinical trial ...

Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial ...

Longeveron Inc LGVN announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheimer's disease. An estimated 6.7 million Americans are living with ...

MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and ...

MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and ...